10-Q · May 12, 2026
AnaptysBio reported Q1 2026 results with revenue of $25.5 million and a net loss per share of $1.84, reflecting a notable decrease in both metrics from the same period last year. The overall trend may deter investor…
Earnings analysis · 10-K
ANAB earnings analysis
Filed September 21, 2026 · Our reading of the company's report
The latest report
AnaptysBio has completed its transformation into a single-segment royalty-management company, with Jemperli royalties and GSK-reported sales growing strongly and continuing-operations income of $176.4 million in the six…
Read full summary
AnaptysBio has completed its transformation into a single-segment royalty-management company, with Jemperli royalties and GSK-reported sales growing strongly and continuing-operations income of $176.4 million in the six months ended June 30, 2026. However, the earnings profile is substantially dependent on GSK and Jemperli, and the reported profit benefited from a non-recurring $181.5 million tax benefit. Unresolved GSK litigation, royalty monetization obligations, competitive pressure, and the company’s limited operating infrastructure keep the overall outlook neutral despite improving royalty economics.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $3.5
- Operating margin
- 60.9%
What stood out
-
Transitioned to royalty-management model
The company completed its April 20, 2026 spin-off and now operates solely as a royalty-management business focused on protecting and returning value from Jemperli and Quimilza collaborations. The spin-off transferred $100.0 million of cash to First Tracks Biotherapeutics.
-
Jemperli royalties continue to grow
Collaboration revenue rose to $53.044 million in the six months ended June 30, 2026 from $50.034 million in the comparable 2025 period. Jemperli royalty revenue increased to $51.203 million from $38.345 million, while GSK reported Jemperli sales of $644.1 million, up more than 30% year over year.
-
Continuing profitability materially improved
Continuing-operations income was $176.358 million, or diluted EPS of $4.71, for the six months ended June 30, 2026, versus $16.574 million and $0.54, respectively, in the comparable 2025 period. The result was heavily supported by a $181.451 million income-tax benefit from releasing deferred-tax valuation allowances.
-
Favorable royalty economics and pipeline
The company’s Jemperli royalty terms provide for royalties of 8% of net sales below $1.0 billion, 12% between $1.0 billion and $1.5 billion, 20% between $1.5 billion and $2.5 billion, and 25% above $2.5 billion. GSK also received FDA acceptance of a supplemental BLA for previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer, with a target action date of February 2027.
-
Lean post-spin operating cash profile
Cash, cash equivalents and investments totaled $164.1 million at June 30, 2026, compared with $211.6 million at December 31, 2025. Continuing-operations operating cash use was only $1.402 million in the six-month period, and royalty monetization liability repayments totaled $19.727 million.
-
Quimilza provides additional royalty optionality
Vanda’s Quimilza has completed two registration-enabling Phase 3 trials; its U.S. BLA was accepted with a December 12, 2026 target action date, and Vanda is eligible for a 10% royalty on net sales. Quimilza also received European Orphan Drug Designation in August 2026.
What to watch
-
Extreme dependence on Jemperli and GSK
Substantially all current and expected revenue depends on GSK’s commercialization of Jemperli, while Anaptys has no control over GSK’s marketing, pricing, payer coverage, development resources, or prioritization decisions. The filing states that the amount and timing of royalty revenue are “unknown and highly uncertain.”
-
GSK collaboration litigation remains unresolved
Anaptys is in litigation with Tesaro and GSK over the collaboration agreement. The company seeks enforcement of the reversion provision and return of dostarlimab rights; post-trial argument is scheduled for October 20, 2026, and a negative outcome could materially affect GSK rights and future financial position.
-
Royalty monetization constrains cash flows
Jemperli royalties are partly monetized: Sagard’s agreement carries a $600.0 million threshold if paid by March 31, 2031, or $675.0 million thereafter, and the royalty-sale liability was $256.493 million at June 30, 2026. Non-cash interest expense was $41.192 million in the six-month period, reducing reported earnings and delaying recovery of future royalties.
-
Competition could reduce royalty stream
Jemperli faces substantial competition, including Keytruda. The filing expects biosimilar competition to materially affect Keytruda between 2028 and 2029 and loss of European market exclusivity in 2031, but states that the effect on Jemperli sales and Anaptys royalties cannot yet be determined.
-
Small operating platform and key-person risk
The company operates with no employees or only a limited number of contractors and relies on consultants and key executives. Following the spin-off, certain management personnel allocate time between two public companies, creating a risk of operational disruption.
-
Post-spin liquidity and transition risk
The spin-off and retained royalty-management model create a substantial change in the company’s financial profile: discontinued operations generated a $45.362 million net loss in the six months ended June 30, 2026, while cash and investments declined by $47.5 million from December 31, 2025 to June 30, 2026.
Management's outlook
No formal revenue or EPS guidance is provided in the 10-KT. Management states that it does not expect to continue incurring net operating losses for at least the next several years and believes existing cash, cash equivalents and investments will fund the current operating plan for at least 12 months from issuance of the financial statements.
Earlier filings 2
10-K · April 28, 2026
AnaptysBio completed the spin-off of First Tracks in April 2026 and reported a sharp operational inflection in H2 2025 driven by collaboration revenue, with pro forma continuing-operations collaboration revenue of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.